Your browser doesn't support javascript.
loading
Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
Wang, Hao; Wang, Ye; Li, Li; Zhou, Han; Lili, Shang; Li, Liao; Yike, Shen; Aixia, Ma.
Afiliación
  • Wang H; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
  • Wang Y; Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, China.
  • Li L; Department of Clinical Pharmacy, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Zhou H; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
  • Lili S; Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, China.
  • Li L; Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing, China.
  • Yike S; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
  • Aixia M; Department of Clinical Pharmacy, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Front Public Health ; 10: 954264, 2022.
Article en En | MEDLINE | ID: mdl-36159269
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Front Public Health Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Front Public Health Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza